Effect of vitamin D supplementation on serum hepcidin levels in non-diabetic chronic kidney disease patients

被引:1
|
作者
Kamboj, Kajal [1 ]
Yadav, Ashok K. [2 ,6 ]
Kumar, Vivek [1 ]
Jha, Vivekanand [3 ,4 ,5 ]
机构
[1] Postgrad Inst Med Educ & Res, Dept Nephrol, Chandigarh, India
[2] Postgrad Inst Med Educ & Res, Dept Expt Med & Biotechnol, Chandigarh, India
[3] George Inst Global Hlth, UNSW, New Delhi, India
[4] Imperial Coll London, Sch Publ Hlth, London, England
[5] Manipal Acad Higher Educ, Prasanna Sch Publ Hlth, Manipal, Karnataka, India
[6] Postgrad Inst Med Educ & Res, Dept Expt Med & Biotechnol, Chandigarh 160012, India
关键词
Cholecalciferol; chronic kidney disease; hepcidin; IRON-METABOLISM; D DEFICIENCY; INDUCTION; ANEMIA;
D O I
10.4103/ijn.ijn_28_23
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Introduction: Vitamin D deficiency and anemia frequently coexist. Moreover, vitamin D deficiency is found to play a role in chronic kidney disease (CKD)-associated anemia. We investigated the effect of cholecalciferol on serum hepcidin levels in vitamin D-deficient, non-diabetic individuals with CKD in a randomized, double-blind, placebo-controlled trial.Methods: This study was performed on stored samples of our previously published randomized, double-blind, placebo-controlled trial of cholecalciferol supplementation in non-diabetic patients with stage III-IV CKD and vitamin D deficiency. Stable patients of either sex, aged 18-70 years, with non-diabetic stage III-IV CKD (estimated glomerular filtration rate between 15 and 60 ml/min/1.73 m(2)), and having serum 25-hydroxyvitamin D-3 [25(OH) D] levels <= 20 ng/ml were included. Participants received either two directly observed oral doses of cholecalciferol (300,000 IU) or matching placebo at baseline and at eight weeks. Follow-up was done at 16 weeks. Serum hepcidin levels were analyzed at baseline and at 16 weeks.Results: A total of 120 CKD patients were enrolled. Serum 25(OH) D levels were similar in the placebo and cholecalciferol groups at baseline (13.21 +/- 4.78 ng/ml and 13.40 +/- 4.42 ng/ml; P = 0.88). After 16 weeks, the serum 25(OH) D levels were found to be increased in the cholecalciferol group but not in the placebo group (between-group difference in mean change 23.40 ng/ml; 95% CI: 19.76 to 27.06; P < 0.001). Serum hepcidin levels were similar at baseline (median [IQR]: 33.6 [8.6-77.8] ng/ml vs. 24.6 [9.3-70.7] ng/ml, P = 0.903) and did not vary between groups at 16 weeks (median [IQR]: 41.5 [10.9-75.0] ng/ml vs. 34.8 [12.3-63.75] ng/ml, P = 0.703).Conclusion: Our study provides preliminary data based on which a larger adequately powered clinical trial can be conducted to conclusively assess the impact of vitamin D supplementation on hepcidin levels and anemia in patients with CKD and vitamin D deficiency.
引用
收藏
页码:444 / +
页数:6
相关论文
共 50 条
  • [41] Referral to nephrologists for chronic kidney disease care: Is non-diabetic kidney disease ignored?
    Navaneethan, Sankar D.
    Nigwekar, Sagar
    Sengodan, Mohan
    Anand, Edwin
    Kadam, Sarika
    Jeevanantham, Vinodh
    Grieff, Marvin
    Choudhry, Wajid
    NEPHRON CLINICAL PRACTICE, 2007, 106 (03): : 113 - 118
  • [42] Serum hepcidin-25 and response to intravenous iron in patients with non-dialysis chronic kidney disease
    Chand, Sourabh
    Ward, Douglas G.
    Ng, Zhi-Yan Valerie
    Hodson, James
    Kirby, Heidi
    Steele, Patricia
    Rooplal, Irina
    Bantugon, Ferly
    Iqbal, Tariq
    Tselepis, Chris
    Drayson, Mark T.
    Whitelegg, Alison
    Chowrimootoo, Marie
    Borrows, Richard
    JOURNAL OF NEPHROLOGY, 2015, 28 (01) : 81 - 88
  • [43] Delayed Gastric Emptying among Indian Patients with Non-Diabetic Chronic Kidney Disease
    Kumar, Madapathi Sampath
    Vinod, Kolar Vishwanath
    Pandit, Nandini
    Sharma, Vivek Kumar
    Dhanapathi, Halanaik
    Parameswaran, Sreejith
    INDIAN JOURNAL OF NEPHROLOGY, 2021, 31 (02) : 135 - 141
  • [44] Effect of Oral and parenteral routes of vitamin D supplementation on serum 25(OH) vitamin D levels in patients with non-alcoholic fatty liver disease
    Alamdari, Arezou Hamzehzadeh
    Ahrabi, Samira
    Khoshbaten, Manouchehr
    Roustaei, Shahram
    Ahrabi, Sara Araqchin
    Jafarabadi, Mohammad Asghari
    CASPIAN JOURNAL OF INTERNAL MEDICINE, 2022, 13 (01) : 23 - 28
  • [45] Relationship between serum vitamin D3 concentration and anaemia in patients with chronic kidney disease in China
    Li, Meng
    Xu, Jun
    Wan, Qin
    He, Qiang
    Ma, Yan
    Tang, Ying-Qian
    Peng, Hong-Ying
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2021, 49 (05)
  • [46] Comparison of Serum Vitamin D Levels Among Patients With Chronic Kidney Disease, Patients in Dialysis, and Renal Transplant Patients
    Cankaya, E.
    Bilen, Y.
    Keles, M.
    Uyanik, A.
    Akbas, M.
    Gungor, A.
    Arslan, S.
    Aydinli, B.
    TRANSPLANTATION PROCEEDINGS, 2015, 47 (05) : 1405 - 1407
  • [47] Cholecalciferol Supplementation in Chronic Kidney Disease: Restoration of Vitamin D Status and Impact on Parathyroid Hormone
    Garcia-Lopes, Miriam G.
    Pillar, Roberta
    Kamimura, Maria Ayako
    Rocha, Lillian A.
    Canziani, Maria Eugenia F.
    Carvalho, Aluizio B.
    Cuppari, Lilian
    ANNALS OF NUTRITION AND METABOLISM, 2012, 61 (01) : 74 - 82
  • [48] T-Cell Subpopulations and Differentiation Bias in Diabetic and Non-Diabetic Patients with Chronic Kidney Disease
    Alacote, Ana Cecilia Granda
    Linares, Gabriela Goyoneche
    Torrico, Maria Gracia Castaneda
    Diaz-Obregon, Daysi Zulema
    Nunez, Michael Bryant Castro
    Carrasco, Alexis German Murillo
    Liendo, Cesar Liendo
    Goche, Katherine Susan Rufasto
    Correa, Victor Arrunategui
    Delgado, Joel de Leon
    BIOMEDICINES, 2025, 13 (01)
  • [49] Oral colonisation and infection by Candida sp in diabetic and non-diabetic patients with chronic kidney disease on dialysis
    de la Rosa-Garcia, Estela
    Miramontes-Zapata, Monica
    Sanchez-Vargas, Luis O.
    Mondragon-Padilla, Arnoldo
    NEFROLOGIA, 2013, 33 (06): : 764 - 770
  • [50] Effect of calcitriol on serum hepcidin in individuals with chronic kidney disease: a randomized controlled trial
    Bhupesh Panwar
    Diane McCann
    Gordana Olbina
    Mark Westerman
    Orlando M. Gutiérrez
    BMC Nephrology, 19